focus -WSS

focus

author：comprehensive 2025-09-06 03:17:32 - browse：7

Outgoing Bristol CEO Giovanni Caforio Emilie Pickering for STAT

It’s changing of the guard time at pharmaceutical giant Bristol Myers Squibb. On Wednesday, CEO Giovanni Caforio will step down. He’ll be replaced by Christopher Boerner, who is currently chief operating officer.

When Caforio took over in May 2015, Bristol was known as a big pharmaceutical firm with the high-flying stock of a biotechnology company, largely due to its role as the company that brought cancer immunotherapy to market. But Bristol stumbled in 2016 when its immunotherapy Opdivo failed to help patients with non-small cell cancer more than chemotherapy. Opdivo remained a big seller, but its failure allowed Merck’s rival Keytruda to move into position to become the best-selling medicine in the world. In 2019, Caforio tried to flip the script, buying the biotech Celgene for $74 billion.

STAT recently sat down with Caforio, 59, to look back on what went wrong and right with his tenure. He also reflected on what it meant to be a physician — and the son of a physician. “We were speaking about patient stories over lunch and dinner, when I was a kid, and I think that drove my passion for medicine,” he said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Mass General Brigham physicians react to latest merger step

hotspot

WSS

Japan raises alarm over China's military, Russia ties and Taiwan tensions in new defense paper

HCA says smaller share of spending going to labor

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Researchers test human milk's ability to repair gut microbiome

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Doctors in states that ban abortion can still help patients

focus

focus

focus

Wildfire smoke exposes gaps in outdoor worker protections

Harvard scientists, with Google, unveil the most detailed brain map ever

Cancer drug shortages should be causing more outrage

Young boy dies in trial for Pfizer Duchenne gene therapy

United colonoscopy coverage change 'may cost lives,' doctors say

Harvard scientists, with Google, unveil the most detailed brain map ever

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Oral obesity drug from Viking Therapeutics hits key early target

At least 13 dead in Texas as scorching temps continue

Overprescribed: High cost isn't America's only drug problem

knowledge

Alzheimer's risk factor APOE4 may be a distinct form of the disease

Trump team launching legal defense fund to help pay legal bills

Medicare Advantage 2025 payments will dip, Biden administration says

HCA says smaller share of spending going to labor

Japan raises alarm over China's military, Russia ties and Taiwan tensions in new defense paper

Trial using CRISPR to edit HIV out of cells disappoints

focus

explore

hotspot

entertainment